menu
    • menu
    [{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"||COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"||COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Colloidal Oatmeal","moa":"||Skin barrier","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"||Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Salicylic Acid","moa":"||COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Orange Grove Bio"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"||COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Research Bridge Partners"},{"orgOrder":0,"company":"Orkla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"||COX-1","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Orkla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orkla \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Orkla \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Salicylic Acid

    Menu

    Salicylic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $33.2 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Divests Certain Non-Core Brands in Dermatology in India to Eris Lifesciences to Focus on Strengt...

                            Details : Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.

                            Product Name : Salicylix

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 16, 2023

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $33.2 million

                            Deal Type : Divestment

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Launches DERMAdoctor’s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on...

                            Details : Salicylic acid helps soften, lift, and clear away flakes of skin on psoriasis plaques. It helps to control the symptoms of psoriasis and provides relief from itching, irritation and redness.

                            Product Name : DERMAdoctor

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 21, 2023

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Alabama at Birmingham

                            Country arrow
                            EPSC
                            Not Confirmed

                            University of Alabama at Birmingham

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colloidal Oatmeal,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : PROCTER AND GAMBLE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bodewell Products for the Treatment of Atopic Dermatitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 04, 2022

                            Lead Product(s) : Colloidal Oatmeal,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : PROCTER AND GAMBLE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asalyxa Bio

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Asalyxa Bio

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Research Bridge Partners

                            Deal Size : $2.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies

                            Details : Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Research Bridge Partners

                            Deal Size : $2.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orkla

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Orkla

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Podiatry

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Investigation to Evaluate The Orkla Corn Plaster

                            Details : Undisclosed

                            Product Name : Orkla Corn Plaster

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 23, 2020

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Podiatry

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asalyxa Bio

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Asalyxa Bio

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Orange Grove Bio

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX...

                            Details : ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 25, 2020

                            Lead Product(s) : Salicylic Acid,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Orange Grove Bio

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Merck Group

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate,Salicylic Acid,Praziquantel

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            March 18, 2020

                            Lead Product(s) : Clobetasol Propionate,Salicylic Acid,Praziquantel

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            VICHY CANADA

                            Canada arrow
                            EPSC
                            Not Confirmed

                            VICHY CANADA

                            Canada arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adapalene,Benzoyl Peroxide,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl P...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 06, 2019

                            Lead Product(s) : Adapalene,Benzoyl Peroxide,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Merck Group

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MSC2499550A,MSC1028703A,Clobetasol Propionate,Salicylic Acid

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Swiss Tropical and Public Health Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2014

                            Lead Product(s) : MSC2499550A,MSC1028703A,Clobetasol Propionate,Salicylic Acid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Swiss Tropical and Public Health Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Almirall

                            Spain arrow
                            EPSC
                            Not Confirmed

                            Almirall

                            Spain arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Almirall

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Kerat...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 13, 2014

                            Lead Product(s) : Fluorouracil,Salicylic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Almirall

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth